clinical trial · NCT04238819
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company·phase2·completed·n = 47
Relapsed Solid TumorRefractory Solid TumorAbemaciclibIrinotecanTemozolomideDinutuximabGM-CSF
brief summary
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.
started
Nov 9, 2020
primary completion
Mar 15, 2024
completion
Aug 19, 2025
last updated
Mar 2, 2026
official title
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol